How big is the South & Central America Cell and Gene Therapy Market?

The South & Central America Cell and Gene Therapy Market is valued at US$ 67.28 Million in 2023, it is projected to reach US$ 184.80 Million by 2031.

What is the CAGR for South & Central America Cell and Gene Therapy Market by (2023 - 2031)?

As per our report South & Central America Cell and Gene Therapy Market, the market size is valued at US$ 67.28 Million in 2023, projecting it to reach US$ 184.80 Million by 2031. This translates to a CAGR of approximately 13.5% during the forecast period.

What segments are covered in this report?

The South & Central America Cell and Gene Therapy Market report typically cover these key segments- 类型（细胞疗法、基因疗法）服务（工艺开发、cGMP 制造、监管服务、生物测定服务）规模（商业化前/研发制造、商业规模制造）

What is the historic period, base year, and forecast period taken for South & Central America Cell and Gene Therapy Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Cell and Gene Therapy Market report: 2025-2031 2023 2021-2023

Who are the major players in South & Central America Cell and Gene Therapy Market?

The South & Central America Cell and Gene Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include: Catalent Inc ; Charles River Laboratories International Inc ; F. Hoffmann-La Roche Ltd ; FUJIFILM Holdings Corp ; Lonza Group AG ; Lotte Corp ; Merck KGaA ; Takara Bio Inc ; Thermo Fisher Scientific Inc.

Who should buy this report?

The South & Central America Cell and Gene Therapy Market report is valuable for diverse stakeholders, including: Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns. Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies. Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry. Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies. Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market. Essentially, anyone involved in or considering involvement in the South & Central America Cell and Gene Therapy Market value chain can benefit from the information contained in a comprehensive market report.

南美和中美细胞和基因治疗市场（主要地区、市场参与者、规模和份额）预测至 2031 年

2023 年，南美和中美细胞和基因治疗市场价值 6728 万美元，预计到 2030 年将达到 1.848 亿美元；预计 2023 年至 2031 年的复合年增长率为 13.5%。

公司战略举措推动南美和中美细胞和基因治疗市场发展

许多参与制造细胞和基因治疗产品的公司专注于合作、扩张、协议、伙伴关系、新产品发布和其他战略发展。这些战略举措帮助他们提高销售额、扩大地理覆盖范围并增强满足庞大客户群的能力。细胞和基因治疗市场的一些重要发展如下：2022 年 3 月，Cellevolve Bio 与西雅图儿童治疗公司合作开发和商业化用于儿童癌症的新型多重 CAR。通过此次合作，两家公司将专注于BrainChild研究项目——一套包含五种多重嵌合抗原受体（CAR）的套件，用于治疗儿童中枢神经系统（CNS）恶性肿瘤。他们计划利用西雅图儿童医院的Cure Factory设施开展新型CAR的早期临床GMP研究。2022年3月，Twist Bioscience Corporation与Kriya Therapeutics, Inc.达成了一项抗体发现协议，旨在利用腺相关病毒（AAV）基因疗法在肿瘤治疗应用中递送抗体。此外，两家公司还计划将Twist的抗体库与Kriya专有的载体工程平台相结合，以发现针对特定靶点的新型抗体，并通过Kriya的基因治疗技术递送。2022年1月，富士胶片株式会社同意收购Atara Biotherapeutics, Inc.旗下一家细胞疗法生产工厂。该工厂将进行扩建，灵活地生产临床和商业细胞疗法，例如同种异体T细胞和CAR-T免疫疗法。

通过合作与伙伴关系开展新业务以保持市场竞争力，有助于加速开发新的细胞和基因治疗制造服务平台。因此，预计主要参与者的这些战略举措将在预测期内为南美和中美细胞和基因治疗市场创造巨大的增长机会。

南美和中美细胞和基因治疗市场概览

营利性组织和非营利组织都在推动巴西先进医疗产品的获取和开发。例如，2024 年 3 月，巴西政府的 Fiocruz 基金会（隶属于巴西卫生部）与 Caring Cross 合作，后者是一家 501(c)(3) 非营利组织，致力于推进尖端医疗治疗方法的开发并促进全球所有患者都能获得治疗。根据这一伙伴关系，政府的目标是在巴西为患有肿瘤、传染病和遗传病的患者建立嵌合抗原受体 (CAR)-T 细胞和干细胞基因疗法的本地生产。这些疗法还包括用于治疗白血病、淋巴瘤和艾滋病毒感染的 CAR-T 细胞疗法。巴西正在尝试在巴西卫生部和公共卫生与研究基金会 Fiocruz 之间建立一种新型合作关系。因此，营利性和非营利性组织采取的举措的增加将推动未来几年的市场增长。

南美和中美细胞和基因治疗市场收入及预测至 2031 年（百万美元）

南美和中美细胞和基因治疗市场细分

南美和中美细胞和基因治疗市场分为类型、服务、规模、最终用户和国家。

根据类型，南美和中美细胞和基因治疗市场分为细胞治疗和基因治疗。细胞治疗部门在 2023 年占据了更大的市场份额。此外，细胞治疗部分又细分为同种异体、自体、病毒载体。此外，基因治疗部分分为非病毒载体和病毒载体。

就服务而言，南美和中美细胞和基因治疗市场分为工艺开发、cGMP 制造、监管服务和生物测定服务。工艺开发部分在 2023 年占据了最大的市场份额。

按规模划分，南美和中美细胞和基因治疗市场分为商业化前/研发制造和商业规模制造。商业化前/研发制造部分在 2023 年占据了更大的市场份额。

根据最终用户，南美和中美细胞和基因治疗市场细分为合同研究

组织、制药和生物制药公司以及学术和研究机构。制药和生物制药公司部门在 2023 年占据了最大的市场份额。

按国家划分，南美和中美细胞和基因治疗市场细分为巴西、阿根廷和南美和中美其他地区。 2023 年，巴西占据了南美和中美细胞和基因治疗市场的主导份额。

Catalent Inc、Charles River Laboratories International In、F. Hoffmann-La Roche Ltd、FUJIFILM Holdings Corp、Lonza Group AG、乐天公司、默克集团、Takara Bio Inc 和赛默飞世尔科技公司是南美和中美细胞和基因治疗市场的一些领先公司。

South & Central America Cell and Gene Therapy Strategic Insights

Strategic insights for South & Central America Cell and Gene Therapy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/south-and-central-america-cell-and-gene-therapy-market-strategic-framework.webp

Get more information on this report

South & Central America Cell and Gene Therapy Report Scope

Report Attribute	Details
Market size in 2023	US$ 67.28 Million
Market Size by 2031	US$ 184.80 Million
Global CAGR (2023 - 2031)	13.5%
Historical Data	2025-2031
Forecast period	2021-2023
Segments Covered	By 类型（细胞疗法、基因疗法） By 服务（工艺开发、cGMP 制造、监管服务、生物测定服务） By 规模（商业化前/研发制造、商业规模制造） By 服务提供商（CDMO、CMO）
Regions and Countries Covered	南美洲和中美洲（巴西、阿根廷、南美洲和中美洲其他地区）南美洲和中美洲（巴西、阿根廷、南美洲和中美洲其他地区）
Market leaders and key company profiles	Catalent Inc Charles River Laboratories International Inc F. Hoffmann-La Roche Ltd FUJIFILM Holdings Corp Lonza Group AG Lotte Corp Merck KGaA Takara Bio Inc Thermo Fisher Scientific Inc.

Get more information on this report

South & Central America Cell and Gene Therapy Regional Insights

The regional scope of South & Central America Cell and Gene Therapy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.